Clinical Trials · NCT06772597
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 18
- Start date
- Mar 2025
- Locations
- 1 site, United States
- Primary endpoint
- Frequency and severity of adverse events (AEs)